Diltiazem Extended-Release Formulations
The question asks about which 240 mg diltiazem capsule is formulated with beads, but the provided evidence does not contain specific information identifying which brand or formulation of 240 mg extended-release diltiazem capsules uses a bead matrix technology.
Available Information from Evidence
The FDA drug label 1 describes immediate-release diltiazem hydrochloride tablets (30 mg, 60 mg, 90 mg, and 120 mg) but does not mention extended-release capsules or bead formulations.
One comparative study 2 evaluated four once-daily controlled-release diltiazem preparations:
- Mono-Tildiem LP 300 mg
- Adizem XL 300 mg
- Cardizem 300 mg
- Dilacor 240 mg
However, this study focused on pharmacokinetic profiles and did not specify which formulations used bead technology versus other controlled-release mechanisms.
Clinical Context
Extended-release diltiazem formulations use various technologies including:
- Bead matrix systems (coated beads within capsules)
- Tablet matrix systems
- Osmotic pump systems
The specific manufacturing technology varies by brand and is typically proprietary information found in individual product labeling rather than clinical guidelines.
Recommendation
To identify which 240 mg diltiazem extended-release capsule uses bead formulation, consult the specific product package insert or contact the manufacturer directly, as this level of pharmaceutical detail is not addressed in the clinical guidelines or FDA labels provided in the evidence.